SG11201509665XA - Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells - Google Patents

Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells

Info

Publication number
SG11201509665XA
SG11201509665XA SG11201509665XA SG11201509665XA SG11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA SG 11201509665X A SG11201509665X A SG 11201509665XA
Authority
SG
Singapore
Prior art keywords
tacrolimus
treating diseases
neuronal cells
protein aggregate
diseases characterised
Prior art date
Application number
SG11201509665XA
Other languages
English (en)
Inventor
Alexandre Akoulitchev
Elizabeth Milway
Elizabeth Jane Mellor
Michael Youdell
Original Assignee
Chronos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chronos Therapeutics Ltd filed Critical Chronos Therapeutics Ltd
Publication of SG11201509665XA publication Critical patent/SG11201509665XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201509665XA 2013-05-24 2014-05-22 Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells SG11201509665XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1309375.2A GB201309375D0 (en) 2013-05-24 2013-05-24 Medical methods and compounds for medical use
PCT/GB2014/051570 WO2014188197A1 (en) 2013-05-24 2014-05-22 Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells

Publications (1)

Publication Number Publication Date
SG11201509665XA true SG11201509665XA (en) 2015-12-30

Family

ID=48784691

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509665XA SG11201509665XA (en) 2013-05-24 2014-05-22 Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells

Country Status (8)

Country Link
US (1) US20160296500A1 (uk)
EP (1) EP3003304A1 (uk)
JP (2) JP2016528171A (uk)
KR (1) KR20160012184A (uk)
CA (1) CA2910006A1 (uk)
GB (1) GB201309375D0 (uk)
SG (1) SG11201509665XA (uk)
WO (1) WO2014188197A1 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600376D0 (en) * 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
WO2019007996A1 (en) * 2017-07-04 2019-01-10 Bionos Biotech, S.L USE OF METALLIC COMPLEXES OF MACROAZAPYRIDINOPHANES IN THE TREATMENT OF DISEASES
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
JPWO2023085363A1 (uk) * 2021-11-12 2023-05-19

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
FR2810995A1 (fr) * 2000-06-29 2002-01-04 Exonhit Therapeutics Sa Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives
AR035411A1 (es) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
GB0410101D0 (en) * 2004-05-06 2004-06-09 Leuven K U Res & Dev Parkinson's disease
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
JP2012171895A (ja) * 2011-02-18 2012-09-10 Nagoya City Univ 毛細血管拡張性失調症治療薬及びその用途

Also Published As

Publication number Publication date
EP3003304A1 (en) 2016-04-13
GB201309375D0 (en) 2013-07-10
JP2016528171A (ja) 2016-09-15
US20160296500A1 (en) 2016-10-13
JP2019104746A (ja) 2019-06-27
CA2910006A1 (en) 2014-11-27
WO2014188197A1 (en) 2014-11-27
KR20160012184A (ko) 2016-02-02

Similar Documents

Publication Publication Date Title
IL267609B (en) Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
ZA201603332B (en) Gla monotherapy for use in cancer treatment
PL3060237T3 (pl) Zmodyfikowane białko przeprogramowujące do stosowania w leczeniu raka
RS65553B1 (sr) Faktor 1 protein za upotrebu u lečenju ili prevenciji bolesti
SG10201706205RA (en) Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
LT2976074T (lt) Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
EP2904014A4 (en) FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
EP2849785A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
HK1224184A1 (zh) 用於治療炎性疾病的化合物、藥物組合物和方法
EP2967062A4 (en) DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION
IL232791A0 (en) Methods of treating excess bilirubin in the blood with stanoporfin
IL274047B (en) Compounds for the treatment of blocking myelin regeneration in diseases associated with the expression of the envelope protein herv-w
SG11201509665XA (en) Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells
IL245541A0 (en) New methods for the treatment of neurodegenerative diseases
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
EP2854784A4 (en) METHOD OF TREATING INFLAMMATORY SKIN DISEASES
IL236714A0 (en) Anti-her2 antibodies with reduced fucosylation for use in cancer therapy
IL239078A0 (en) Protein for use in the treatment of eye diseases
EP2966973A4 (en) IMPROVED METHODS OF GRAIN PROCESSING WITH OZONE
PT2836176T (pt) Técnica para tratar presbiopia
IL236505B (en) Enoxacin for use in the treatment of motor neuron diseases
ZA201302565B (en) Methods for treating hyperuricemia and related diseases
HUE048942T2 (hu) Antraciklin-származékok tumorbetegségek kezeléséhez